Saskia K. Klein

Groningen, GR, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 65 publications

Subtype-specific outcome after allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis: a registry study of the European competence network on mastocytosis.

Subtype-specific outcome after allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis: a registry study of the European competence network on mastocytosis.

Journal: Experimental hematology & oncology

Published: June 21, 2026

Development of a High-Sensitivity Multiplex mRNA-Based KIT D816V Droplet Digital PCR Assay and Correlation with Tumor Load in Systemic Mastocytosis.

Development of a High-Sensitivity Multiplex mRNA-Based KIT D816V Droplet Digital PCR Assay and Correlation with Tumor Load in Systemic Mastocytosis.

Journal: International journal of molecular sciences

Published: May 08, 2026

Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study.

Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study.

Journal: Journal of hematology & oncology

Published: March 15, 2026

Target Attainment and Clinical and Biochemical Parameters Associated with the Pharmacokinetics of 12 Tyrosine Kinase Inhibitors.

Target Attainment and Clinical and Biochemical Parameters Associated with the Pharmacokinetics of 12 Tyrosine Kinase Inhibitors.

Journal: Clinical pharmacokinetics

Published: February 03, 2026

Flow Cytometry-Based Measurable Residual Disease Assessment in Patients With Acute Myeloid Leukemia Receiving Non-Intensive Chemotherapy.

Flow Cytometry-Based Measurable Residual Disease Assessment in Patients With Acute Myeloid Leukemia Receiving Non-Intensive Chemotherapy.

Journal: American journal of hematology

Published: January 29, 2026

Anti-thymocyte globulin-based treatment frequently leads to enduring treatment success in both old and young adult patients with aplastic anaemia: a real-world analysis from the Dutch aplastic anaemia registry.

Anti-thymocyte globulin-based treatment frequently leads to enduring treatment success in both old and young adult patients with aplastic anaemia: a real-world analysis from the Dutch aplastic anaemia registry.

Journal: Annals of hematology

Published: December 05, 2025

Pharmacological boosting of azacitidine/venetoclax in acute myeloid leukemia.

Pharmacological boosting of azacitidine/venetoclax in acute myeloid leukemia.

Journal: Blood neoplasia

Published: December 02, 2025

Integrative preclinical strategy for pharmacokinetic profiling and candidate selection of 3-hydroxypropanamidines: a promising antimalarial class.

Integrative preclinical strategy for pharmacokinetic profiling and candidate selection of 3-hydroxypropanamidines: a promising antimalarial class.

Journal: Malaria journal

Published: October 26, 2025

Structure-Activity Relationships of 3-Hydroxypropanamidines (HPAs) with Potent In Vivo Antimalarial Activity.

Structure-Activity Relationships of 3-Hydroxypropanamidines (HPAs) with Potent In Vivo Antimalarial Activity.

Journal: Journal of medicinal chemistry

Published: September 08, 2025

Uncovering the ultra-frail: A distinct subgroup in non-transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome.

Uncovering the ultra-frail: A distinct subgroup in non-transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome.

Journal: HemaSphere

Published: July 31, 2025

Interim analysis of a multicenter study on patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia: the RODEO study.

Interim analysis of a multicenter study on patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia: the RODEO study.

Journal: Haematologica

Published: June 26, 2025

Venetoclax plus hypomethylating agents as a bridge to transplant or donor lymphocyte infusion in relapsed/ refractory acute myeloid leukemia.

Venetoclax plus hypomethylating agents as a bridge to transplant or donor lymphocyte infusion in relapsed/ refractory acute myeloid leukemia.

Journal: Haematologica

Published: May 08, 2025

Showing 1-12 of 65

Last Updated: 09/26/2026